Open Access Research Article Article ID: JCRO-9-196

    Evaluation of clinical efficacy and safety of Bibrocathol 2% eye ointment in the treatment of Chronic Blepharoconjunctivitis

    Elena Yani, Sergey Astakhov, Vladimir Brzheskiy, Evgeniy Egorov, Alexey Seleznev, Dorothea Groß* and Heidi Opitz

    Purpose: To assess the efficacy and safety of bibrocathol 2% eye ointment in patients with chronic blepharoconjunctivitis. 

    Materials and methods: This was a multi-center, randomized, double-masked, placebo-controlled, parallel-group, phase III study. Patients with chronic blepharoconjunctivitis were randomized to apply either bibrocathol 2% (n = 100) or placebo (n = 100) three times a day for 14 days. The primary efficacy endpoint was the change from baseline to Day 15(+1 day) in the total score of signs summarizing the investigators’ assessment of the severity of lid oedema, lid erythema, debris, hyperemia, and pouting of Meibomian glands based on slit-lamp examination (modified Intention-to-treat (mITT) set). Safety endpoints included visual acuity, intraocular pressure, and adverse events. Investigators and patients performed an overall assessment of treatment tolerability.

    Results: On Day 15(+1 day) the least square (LS) mean change from baseline in the total sum score of signs was -8.62 (95% CI: -9.16; -8.08) in the bibrocathol group and -6.00 (95%CI: -6.54; -5.45) in the placebo group. The LS means the difference between treatment groups was statistically significant in favor of bibrocathol (-2.63 [95% CI: -3.36, -1.89], p < 0.001). Bibrocathol was statistically significantly superior to placebo in reduction of the individual ocular signs scores and the patient’s-assessed ocular discomfort severity (p < 0.001). No safety issues were observed concerning visual acuity, intraocular pressure, and the occurrence of adverse events.

    Conclusions: The study showed superior efficacy of two weeks of treatment with bibrocathol versus placebo in reducing signs and symptoms of chronic blepharoconjunctivitis. Treatment with bibrocathol 2% eye ointment was safe and well-tolerated.


    Published on: May 17, 2022 Pages: 8-14

    Full Text PDF Full Text HTML DOI: 10.17352/2455-1414.000096
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on JCRO

    Help ? Google Reviews 11